J & J report Q2 Double Digit Growth in Market

J & J have released their Q2 2008 financials and present a positive result for the hemostasis market.
Regarding the Ethicon division report "... Ethicon worldwide sales grew operationally by 6% with the U.S. up 7% and sales outside the U.S. growing operationally by 5%. Solid growth in sutures and double-digit growth in homeostasis and mesh products were the major contributors to growth in the quarter."
Commenting on the offer for the Ethicon Woundcare segment by One Equity Partners, Dominic Caruso (CFO) remained tight-lipped saying "If the offer is accepted and the closing conditions are satisfied, the proposed transaction would be expected to close later in 2008. It would be premature to say anything more about this pending transaction at this time. "

Cohera get grant for Tissuglu

Cohera Medical Inc. today announced that it has been selected to receive a Phase II Small Business Innovation Research (SBIR) grant of $1.5 million for the ongoing development of TissuGlu, a novel surgical adhesive for application in plastic surgery.
The Phase II SBIR grant, awarded by the National Institutes of Health (NIH), will fund work to finalize the pre-clinical testing that will support submission of an Investigational Device Exemption (IDE) to the Food and Drug Administration (FDA) for approval to initiate human clinical trials. In the second year of the award, human clinical trials will be initiated to establish the product's safety and efficacy.
"Cohera is honored to receive this prestigious and selective award in the current highly competitive environment," said Patrick Daly, president and CEO of Cohera Medical. "Through this award, the NIH acknowledges the innovative nature of Cohera's technology as well as the robust commercial potential of TissuGlu. Our ongoing plans for TissuGlu seek to establish its safety and efficacy as a surgical adhesive to reduce fluid accumulation and the need for drains after surgery. The grant follows the successful completion of the Phase I SBIR project, which established the efficacy of the product formulation and the dispenser device design in preliminary studies."

Effect of Fibrin Sealant on Drain Output and Duration of Hospitalization

Objective. To determine if fibrin sealant can decrease postoperative drain output and length of stay (LOS) after multilevel anterior cervical fusions.
Summary of Background Data. Despite careful hemostasis, bleeding after anterior cervical fusion can occur and may be life threatening. Although fibrin sealants are commonly used for hemostasis, no studies have been published on the efficacy of these products in achieving hemostasis after anterior cervical surgery.
Conclusion. Application of fibrin sealant at the end of multilevel anterior cervical fusion can significantly decrease postoperative drain output and LOS.
Abstract HERE